Evidence map›Paper›PMID 30018277›Full record

ArticleInternational journal of molecular sciences2018

The Dietary Antioxidant Piceatannol Inhibits Adipogenesis of Human Adipose Mesenchymal Stem Cells and Limits Glucose Transport and Lipogenic Activities in Adipocytes.

Christian Carpéné, Héctor Pejenaute, Raquel Del Moral, Nathalie Boulet, Elizabeth Hijona, Fernando Andrade, Maria Jesùs Villanueva-Millán, Leixuri Aguirre, José Miguel Arbones-Mainar

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

Christian CarpénéINSERM U1048, Institute of Metabolic and Cardiovascular Diseases (I2MC), Paul Sabatier University, 31059 Toulouse, France. christian.carpene@inserm.fr.
Héctor PejenauteAdipocyte and Fat Biology Laboratory (AdipoFat), Unidad de Investigación Traslacional, Instituto Aragonés de Ciencias de la Salud (IACS), Instituto de Investigación Sanitaria (IIS) Aragon, 50009 Zaragoza, Spain. fles@usj.es.
Raquel Del MoralAdipocyte and Fat Biology Laboratory (AdipoFat), Unidad de Investigación Traslacional, Instituto Aragonés de Ciencias de la Salud (IACS), Instituto de Investigación Sanitaria (IIS) Aragon, 50009 Zaragoza, Spain. email@adipofat.com.
Nathalie BouletINSERM U1048, Institute of Metabolic and Cardiovascular Diseases (I2MC), Paul Sabatier University, 31059 Toulouse, France. nathalie.boulet@inserm.fr.
Elizabeth HijonaDepartment of Gastroenterology, University of Basque Country (UPV/EHU), Biodonostia Research Institute, 20014 San Sebastián, Spain. ELIZABETH.HIJONA@biodonostia.org.
Fernando AndradeDivision of Metabolism, Cruces University Hospital and BioCruces Health Research Institute, Plaza de Cruces s/n, 48903 Barakaldo, Spain. FERNANDO.ANDRADELODEIRO@osakidetza.eus.
Maria Jesùs Villanueva-MillánHIV and Associated Metabolic Alterations Unit, Infectious Diseases Department, Center for Biomedical Research of La Rioja (CIBIR), 26006 Logroño, Spain. chusmillan85@gmail.com.
Leixuri AguirreNutrition and Obesity Group, Department of Nutrition and Food Science, Faculty of Pharmacy and Lucio Lascaray Research Center, University of the Basque Country (UPV/EHU), 01006 Vitoria, Spain. leixuri.aguirre@ehu.eus.
José Miguel Arbones-MainarAdipocyte and Fat Biology Laboratory (AdipoFat), Unidad de Investigación Traslacional, Instituto Aragonés de Ciencias de la Salud (IACS), Instituto de Investigación Sanitaria (IIS) Aragon, 50009 Zaragoza, Spain. jmarbones.iacs@aragon.es.ORCID 0000-0002-8982-3737
Instituto de Investigación Sanitaria Aragón · ESUniversité Toulouse III - Paul Sabatier · FRBioCruces Health research Institute · ESBiogipuzkoa Health Research Institute · ESCenter for Biomedical Research of La Rioja · ESInstituto de Salud Carlos III · ESUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phenolic compounds are among the most investigated herbal remedies, as is especially the case for resveratrol. Many reports have shown its anti-aging properties and the ability to reduce obesity and diabetes induced by high-fat diet in mice. However, such beneficial effects hardly translate from animal models to humans. The scientific community has therefore tested whether other plant phenolic compounds may surpass the effects of resveratrol. In this regard, it has been reported that piceatannol reproduces in rodents the anti-obesity actions of its parent polyphenol. However, the capacity of piceatannol to inhibit adipocyte differentiation in humans has not been characterized so far. Here, we investigated whether piceatannol was antiadipogenic and antilipogenic in human preadipocytes. Human mesenchymal stem cells (hMSC), isolated from adipose tissues of lean and obese individuals, were differentiated into mature adipocytes with or without piceatannol, and their functions were explored. Fifty μM of piceatannol deeply limited synthesis/accumulation of lipids in both murine and hMSC-derived adipocytes. Interestingly, this phenomenon occurred irrespective of being added at the earlier or later stages of adipocyte differentiation. Moreover, piceatannol lowered glucose transport into adipocytes and decreased the expression of key elements of the lipogenic pathway (PPARγ, FAS, and GLUT4). Thus, the confirmation of the antiadipogenic properties of piceatanol in vitro warrants the realization of clinical studies for the application of this compound in the treatment of the metabolic complications associated with obesity.

Indexed as

3T3-L1 CellsAdipocytesAdipogenesisAdipose TissueAdultAnimalsAntioxidantsBiological TransportCells, CulturedDietary Supplementsfas ReceptorGlucoseGlucose Transporter Type 4HumansLipogenesisMesenchymal Stem Cells3,3',4,5'-tetrahydroxystilbeneAntioxidantsfas ReceptorGlucoseGlucose Transporter Type 4PPAR gammaStilbenesadipogenesisfat cellshydrogen peroxideresveratrolstilbenoids

Identifiers

PMID30018277
PMCPMC6073844
OpenAlexW2883867717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.